Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02311881 · ClinicalTrials.gov registry record · Phase 3
A 12-Week Efficacy Study of Paracetamol 1000mg Sustained-release Tablets in Patients With Osteoarthritis
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 960
- Enrollment target
NCT02311881 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 960 participants.
The verdict
NCT02311881, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 960 participants
- Enrollment target
Study Summary
The purpose of the study is to determine whether paracetamol 1000 mg sustained-release (SR) tablets administered orally, twice daily are effective and safe in the treatment of patients with osteoarthritis of the knee or hip.
Interventions
- DRUG Placebo
- DRUG Paracetamol 1000 mg SR tablets
- DRUG Paracetamol 665 mg SR tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 960 participants |
| Start Date | 2015-01 |
| Est. Completion | 2016-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02311881
The ClinicalTrials.gov registry entry for NCT02311881 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 960 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02311881 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02311881 about?
NCT02311881 is a clinical study titled "A 12-Week Efficacy Study of Paracetamol 1000mg Sustained-release Tablets in Patients With Osteoarthritis". The purpose of the study is to determine whether paracetamol 1000 mg sustained-release (SR) tablets administered orally, twice daily are effective and safe in the treatment of patients with osteoarthritis of the knee or hip.
What is the current status of trial NCT02311881?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 960 participants. The study started on 2015-01. Estimated completion is 2016-02.
What interventions are being tested in trial NCT02311881?
The interventions under investigation include: Placebo (DRUG), Paracetamol 1000 mg SR tablets (DRUG), Paracetamol 665 mg SR tablets (DRUG).
Who is sponsoring clinical trial NCT02311881?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.